Ticrynafen

Identification

Name
Ticrynafen
Accession Number
DB04831
Type
Small Molecule
Groups
Withdrawn
Description

Ticrynafen, or tienilic acid, is a diuretic drug with uric acid-lowering (uricosuric) action, formerly marketed for the treatment of hypertension. It was withdrawn in 1982, shortly after its introduction to the market, after case reports in the United States indicated a link between the use of ticrynafen and hepatitis. (Manier et al., 1982)

Structure
Thumb
Synonyms
  • (2,3-Dichloro-4-(2-thenoyl)phenoxy)acetic acid
  • (2,3-Dichloro-4-(2-thienylcarbonyl)phenoxy)acetic acid
  • (2,3-Dichloro-4-(2-thiophenecarbonyl)phenoxy)acetic acid
  • 4-(2-Theonyl)-2,3-dichlorphenoxyessigsaeure
  • 4-(2-Thienylketo)-2,3-dichlorophenoxyacetic acid
  • Acide tienilique
  • Acido tienilico
  • Acidum tienilicum
  • Thienylic acid
  • Tienilic acid
  • Tienilico acido
International/Other Brands
Diflurex / Selacryn / Ticrex
Categories
UNII
HC95205SY4
CAS number
40180-04-9
Weight
Average: 331.171
Monoisotopic: 329.952034848
Chemical Formula
C13H8Cl2O4S
InChI Key
AGHANLSBXUWXTB-UHFFFAOYSA-N
InChI
InChI=1S/C13H8Cl2O4S/c14-11-7(13(18)9-2-1-5-20-9)3-4-8(12(11)15)19-6-10(16)17/h1-5H,6H2,(H,16,17)
IUPAC Name
2-[2,3-dichloro-4-(thiophene-2-carbonyl)phenoxy]acetic acid
SMILES
OC(=O)COC1=C(Cl)C(Cl)=C(C=C1)C(=O)C1=CC=CS1

Pharmacology

Indication

For the treatment of hypertension.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Ticrynafen.Experimental
AcebutololAcebutolol may increase the hypotensive activities of Ticrynafen.Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Ticrynafen.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Ticrynafen.Approved, Investigational
AliskirenTicrynafen may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Ticrynafen.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Ticrynafen.Illicit
AlprenololAlprenolol may increase the hypotensive activities of Ticrynafen.Approved, Withdrawn
AmbrisentanTicrynafen may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineTicrynafen may increase the hypotensive activities of Amifostine.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Ticrynafen.Approved
AtenololAtenolol may increase the hypotensive activities of Ticrynafen.Approved
BenazeprilBenazepril may increase the hypotensive activities of Ticrynafen.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Ticrynafen.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Ticrynafen.Withdrawn
BepridilBepridil may increase the hypotensive activities of Ticrynafen.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Ticrynafen.Approved
BethanidineBethanidine may increase the hypotensive activities of Ticrynafen.Approved
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Ticrynafen.Experimental, Illicit, Withdrawn
BietaserpineBietaserpine may increase the hypotensive activities of Ticrynafen.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Ticrynafen.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Ticrynafen.Approved
BosentanBosentan may increase the hypotensive activities of Ticrynafen.Approved, Investigational
BQ-123Ticrynafen may increase the hypotensive activities of BQ-123.Investigational
BretyliumBretylium may increase the hypotensive activities of Ticrynafen.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Ticrynafen.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Ticrynafen.Experimental
BupranololTicrynafen may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Ticrynafen.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ticrynafen.Approved, Illicit, Vet Approved
CadralazineCadralazine may increase the hypotensive activities of Ticrynafen.Experimental
CafedrineTicrynafen may increase the hypotensive activities of Cafedrine.Investigational
CandesartanCandesartan may increase the hypotensive activities of Ticrynafen.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Ticrynafen.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Ticrynafen.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Ticrynafen.Illicit, Vet Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Ticrynafen.Withdrawn
CarteololCarteolol may increase the hypotensive activities of Ticrynafen.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Ticrynafen.Approved, Investigational
CeliprololTicrynafen may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChlorothiazideChlorothiazide may increase the hypotensive activities of Ticrynafen.Approved, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Ticrynafen.Approved
CicletanineTicrynafen may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilCilazapril may increase the hypotensive activities of Ticrynafen.Approved
ClonidineClonidine may increase the hypotensive activities of Ticrynafen.Approved
CloranololTicrynafen may increase the hypotensive activities of Cloranolol.Experimental
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Ticrynafen.Approved, Illicit
CryptenamineCryptenamine may increase the hypotensive activities of Ticrynafen.Approved
CyclopenthiazideTicrynafen may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideCyclothiazide may increase the hypotensive activities of Ticrynafen.Approved
DebrisoquinDebrisoquin may increase the hypotensive activities of Ticrynafen.Approved
DelaprilTicrynafen may increase the hypotensive activities of Delapril.Experimental
DeserpidineTicrynafen may increase the hypotensive activities of Deserpidine.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Ticrynafen.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ticrynafen.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Ticrynafen.Approved
DiazoxideDiazoxide may increase the hypotensive activities of Ticrynafen.Approved
diethylnorspermineTicrynafen may increase the hypotensive activities of diethylnorspermine.Investigational
DihydralazineDihydralazine may increase the hypotensive activities of Ticrynafen.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ticrynafen.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ticrynafen.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ticrynafen.Experimental, Illicit
DiltiazemDiltiazem may increase the hypotensive activities of Ticrynafen.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ticrynafen.Approved, Illicit
DorzolamideDorzolamide may increase the hypotensive activities of Ticrynafen.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Ticrynafen.Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Ticrynafen.Investigational
EfonidipineTicrynafen may increase the hypotensive activities of Efonidipine.Approved
EnalaprilEnalapril may increase the hypotensive activities of Ticrynafen.Approved, Vet Approved
EnalaprilatTicrynafen may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Ticrynafen.Experimental
EpanololTicrynafen may increase the hypotensive activities of Epanolol.Experimental
EpoprostenolEpoprostenol may increase the hypotensive activities of Ticrynafen.Approved
EprosartanEprosartan may increase the hypotensive activities of Ticrynafen.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ticrynafen.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Ticrynafen.Illicit, Vet Approved
FelodipineFelodipine may increase the hypotensive activities of Ticrynafen.Approved, Investigational
FenoldopamFenoldopam may increase the hypotensive activities of Ticrynafen.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ticrynafen.Approved, Illicit, Investigational, Vet Approved
Ferulic acidTicrynafen may increase the hypotensive activities of Ferulic acid.Experimental
FosinoprilFosinopril may increase the hypotensive activities of Ticrynafen.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Ticrynafen.Approved, Vet Approved
GuanabenzGuanabenz may increase the hypotensive activities of Ticrynafen.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Ticrynafen.Approved
GuanazodineTicrynafen may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Ticrynafen.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Ticrynafen.Approved, Investigational
GuanoclorTicrynafen may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzTicrynafen may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanTicrynafen may increase the hypotensive activities of Guanoxan.Experimental
HarmalineHarmaline may increase the hypotensive activities of Ticrynafen.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Ticrynafen.Approved, Illicit
HexamethoniumTicrynafen may increase the hypotensive activities of Hexamethonium.Experimental
HydracarbazineHydracarbazine may increase the hypotensive activities of Ticrynafen.Experimental
HydralazineHydralazine may increase the hypotensive activities of Ticrynafen.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Ticrynafen.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Ticrynafen.Approved, Illicit
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Ticrynafen.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ticrynafen.Approved, Illicit
IloprostIloprost may increase the hypotensive activities of Ticrynafen.Approved, Investigational
ImidaprilTicrynafen may increase the hypotensive activities of Imidapril.Investigational
IndapamideIndapamide may increase the hypotensive activities of Ticrynafen.Approved
IndenololTicrynafen may increase the hypotensive activities of Indenolol.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Ticrynafen.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Ticrynafen.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Ticrynafen.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Ticrynafen.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Ticrynafen.Approved
IsradipineIsradipine may increase the hypotensive activities of Ticrynafen.Approved
KetanserinKetanserin may increase the hypotensive activities of Ticrynafen.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Ticrynafen.Approved
LabetalolLabetalol may increase the hypotensive activities of Ticrynafen.Approved
LacidipineTicrynafen may increase the hypotensive activities of Lacidipine.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Ticrynafen.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Ticrynafen.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ticrynafen.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ticrynafen.Approved
LinsidomineTicrynafen may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Ticrynafen.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Ticrynafen.Illicit
LofexidineTicrynafen may increase the hypotensive activities of Lofexidine.Approved, Investigational
LosartanLosartan may increase the hypotensive activities of Ticrynafen.Approved
MacitentanTicrynafen may increase the hypotensive activities of Macitentan.Approved
ManidipineTicrynafen may increase the hypotensive activities of Manidipine.Approved
MebanazineMebanazine may increase the hypotensive activities of Ticrynafen.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Ticrynafen.Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Ticrynafen.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Ticrynafen.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Ticrynafen.Approved, Illicit
MethoserpidineTicrynafen may increase the hypotensive activities of Methoserpidine.Experimental
MethyldopaMethyldopa may increase the hypotensive activities of Ticrynafen.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Ticrynafen.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Ticrynafen.Approved, Investigational
MetipranololMetipranolol may increase the hypotensive activities of Ticrynafen.Approved
MetolazoneMetolazone may increase the hypotensive activities of Ticrynafen.Approved
MetoprololMetoprolol may increase the hypotensive activities of Ticrynafen.Approved, Investigational
MetyrosineTicrynafen may increase the hypotensive activities of Metyrosine.Approved
MibefradilMibefradil may increase the hypotensive activities of Ticrynafen.Withdrawn
MinaprineMinaprine may increase the hypotensive activities of Ticrynafen.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Ticrynafen.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Ticrynafen.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Ticrynafen.Approved
MoexiprilMoexipril may increase the hypotensive activities of Ticrynafen.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Ticrynafen.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Ticrynafen.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Ticrynafen.Approved
MuzolimineTicrynafen may increase the hypotensive activities of Muzolimine.Experimental
NadololNadolol may increase the hypotensive activities of Ticrynafen.Approved
NaftopidilTicrynafen may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ticrynafen.Approved
NebivololTicrynafen may increase the hypotensive activities of Nebivolol.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Ticrynafen.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Ticrynafen.Approved
NicomorphineThe risk or severity of adverse effects can be increased when Nicomorphine is combined with Ticrynafen.Experimental
NicorandilTicrynafen may increase the hypotensive activities of Nicorandil.Approved
NiguldipineTicrynafen may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineTicrynafen may increase the hypotensive activities of Nilvadipine.Approved
NimodipineNimodipine may increase the hypotensive activities of Ticrynafen.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Ticrynafen.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Ticrynafen.Approved
NitroprussideNitroprusside may increase the hypotensive activities of Ticrynafen.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Ticrynafen.Approved, Illicit
ObinutuzumabTicrynafen may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Ticrynafen.Withdrawn
OlmesartanOlmesartan may increase the hypotensive activities of Ticrynafen.Approved, Investigational
OmapatrilatOmapatrilat may increase the hypotensive activities of Ticrynafen.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Ticrynafen.Approved, Illicit
OxprenololOxprenolol may increase the hypotensive activities of Ticrynafen.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ticrynafen.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ticrynafen.Approved, Investigational, Vet Approved
PargylinePargyline may increase the hypotensive activities of Ticrynafen.Approved
PenbutololPenbutolol may increase the hypotensive activities of Ticrynafen.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ticrynafen.Approved, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Ticrynafen.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Ticrynafen.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Ticrynafen.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ticrynafen.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Ticrynafen.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Ticrynafen.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Ticrynafen.Withdrawn
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Ticrynafen.Experimental
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Ticrynafen.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Ticrynafen.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Ticrynafen.Approved
PinacidilPinacidil may increase the hypotensive activities of Ticrynafen.Withdrawn
PindololPindolol may increase the hypotensive activities of Ticrynafen.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Ticrynafen.Investigational
PirlindolePirlindole may increase the hypotensive activities of Ticrynafen.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Ticrynafen.Withdrawn
PolythiazidePolythiazide may increase the hypotensive activities of Ticrynafen.Approved
PrazosinPrazosin may increase the hypotensive activities of Ticrynafen.Approved
PropranololPropranolol may increase the hypotensive activities of Ticrynafen.Approved, Investigational
QuinaprilQuinapril may increase the hypotensive activities of Ticrynafen.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Ticrynafen.Approved
RamiprilRamipril may increase the hypotensive activities of Ticrynafen.Approved
RasagilineRasagiline may increase the hypotensive activities of Ticrynafen.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ticrynafen.Approved
RemikirenRemikiren may increase the hypotensive activities of Ticrynafen.Approved
RescinnamineTicrynafen may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Ticrynafen.Approved
RilmenidineRilmenidine may increase the hypotensive activities of Ticrynafen.Investigational
RiociguatTicrynafen may increase the hypotensive activities of Riociguat.Approved
RituximabTicrynafen may increase the hypotensive activities of Rituximab.Approved
SafrazineSafrazine may increase the hypotensive activities of Ticrynafen.Withdrawn
SaprisartanSaprisartan may increase the hypotensive activities of Ticrynafen.Experimental
SelegilineSelegiline may increase the hypotensive activities of Ticrynafen.Approved, Investigational, Vet Approved
SelexipagTicrynafen may increase the hypotensive activities of Selexipag.Approved
SildenafilSildenafil may increase the antihypertensive activities of Ticrynafen.Approved, Investigational
SitaxentanTicrynafen may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium phosphateTicrynafen may increase the nephrotoxic activities of Sodium phosphate.Approved
SpiraprilSpirapril may increase the hypotensive activities of Ticrynafen.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ticrynafen.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Ticrynafen.Approved, Investigational
TalinololTicrynafen may increase the hypotensive activities of Talinolol.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Ticrynafen.Approved
TelmisartanTelmisartan may increase the hypotensive activities of Ticrynafen.Approved, Investigational
TemocaprilTicrynafen may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerlipressinTerlipressin may increase the hypotensive activities of Ticrynafen.Approved, Investigational
TetrahydropalmatineTicrynafen may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TheodrenalineTicrynafen may increase the hypotensive activities of Theodrenaline.Investigational
TiboloneTicrynafen may increase the hypotensive activities of Tibolone.Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Ticrynafen.Experimental
TimololTimolol may increase the hypotensive activities of Ticrynafen.Approved
TolazolineTolazoline may increase the hypotensive activities of Ticrynafen.Approved, Vet Approved
TolonidineTicrynafen may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Ticrynafen.Approved
TorasemideTorasemide may increase the hypotensive activities of Ticrynafen.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Ticrynafen.Approved, Investigational
TrandolaprilTrandolapril may increase the hypotensive activities of Ticrynafen.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Ticrynafen.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Ticrynafen.Approved
TravoprostTravoprost may increase the hypotensive activities of Ticrynafen.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Ticrynafen.Approved, Investigational
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Ticrynafen.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Ticrynafen.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Ticrynafen.Approved
UdenafilUdenafil may increase the antihypertensive activities of Ticrynafen.Approved, Investigational
UnoprostoneTicrynafen may increase the hypotensive activities of Unoprostone.Approved
UrapidilUrapidil may increase the hypotensive activities of Ticrynafen.Investigational
ValsartanValsartan may increase the hypotensive activities of Ticrynafen.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Ticrynafen.Approved
VincamineTicrynafen may increase the hypotensive activities of Vincamine.Experimental
VinpocetineTicrynafen may increase the hypotensive activities of Vinpocetine.Investigational
XipamideTicrynafen may increase the hypotensive activities of Xipamide.Experimental
XylometazolineTicrynafen may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Ticrynafen.Approved, Vet Approved
ZofenoprilTicrynafen may increase the hypotensive activities of Zofenopril.Experimental
Food Interactions
Not Available

References

Synthesis Reference

Harold Graboyes, "Method for preparing ticrynafen." U.S. Patent US4107179, issued April, 1977.

US4107179
General References
  1. Manier JW, Chang WW, Kirchner JP, Beltaos E: Hepatotoxicity associated with ticrynafen--a uricosuric diuretic. Am J Gastroenterol. 1982 Jun;77(6):401-4. [PubMed:7091125 ]
External Links
KEGG Drug
D02386
KEGG Compound
C11702
PubChem Compound
38409
PubChem Substance
46505485
ChemSpider
35204
BindingDB
50090674
ChEBI
9590
ChEMBL
CHEMBL267744
Wikipedia
Ticrynafen
ATC Codes
C03CC02 — Tienilic acid
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)149 °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility0.00254 mg/mLALOGPS
logP4.09ALOGPS
logP3.87ChemAxon
logS-5.1ALOGPS
pKa (Strongest Acidic)3.22ChemAxon
pKa (Strongest Basic)-5ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area63.6 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity75.68 m3·mol-1ChemAxon
Polarizability30.45 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.913
Blood Brain Barrier+0.8914
Caco-2 permeable-0.5564
P-glycoprotein substrateNon-substrate0.6678
P-glycoprotein inhibitor INon-inhibitor0.8785
P-glycoprotein inhibitor IINon-inhibitor0.9398
Renal organic cation transporterNon-inhibitor0.875
CYP450 2C9 substrateNon-substrate0.7168
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.6863
CYP450 1A2 substrateNon-inhibitor0.5326
CYP450 2C9 inhibitorNon-inhibitor0.6725
CYP450 2D6 inhibitorNon-inhibitor0.908
CYP450 2C19 inhibitorNon-inhibitor0.8257
CYP450 3A4 inhibitorNon-inhibitor0.9104
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.638
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.8764
BiodegradationNot ready biodegradable0.5809
Rat acute toxicity2.5618 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9848
hERG inhibition (predictor II)Non-inhibitor0.9193
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of chemical entities known as aryl-phenylketones. These are aromatic compounds containing a ketone substituted by one aryl group, and a phenyl group.
Kingdom
Chemical entities
Super Class
Organic compounds
Class
Organic oxygen compounds
Sub Class
Organooxygen compounds
Direct Parent
Aryl-phenylketones
Alternative Parents
Chlorophenoxyacetates / Thiophene carboxylic acids and derivatives / Phenoxy compounds / Phenol ethers / Dichlorobenzenes / Benzoyl derivatives / Alkyl aryl ethers / Aryl chlorides / Vinylogous halides / Heteroaromatic compounds
show 5 more
Substituents
Aryl-phenylketone / Chlorophenoxyacetate / Phenoxyacetate / Phenoxy compound / 1,2-dichlorobenzene / Benzoyl / Phenol ether / Thiophene carboxylic acid or derivatives / Alkyl aryl ether / Halobenzene
show 18 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
aromatic ether, monocarboxylic acid, thiophenes, dichlorobenzene, aromatic ketone (CHEBI:9590 )

Enzymes

Details
1. Cytochrome P450 2C9
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Hutzler JM, Balogh LM, Zientek M, Kumar V, Tracy TS: Mechanism-based inactivation of cytochrome P450 2C9 by tienilic acid and (+/-)-suprofen: a comparison of kinetics and probe substrate selection. Drug Metab Dispos. 2009 Jan;37(1):59-65. doi: 10.1124/dmd.108.023358. Epub 2008 Oct 6. [PubMed:18838506 ]

Drug created on September 11, 2007 14:55 / Updated on October 02, 2017 05:39